Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ATYRBullishIndustry Newsnews

High materiality8/10

aTyr Aligns Phase 3 Protocol for Efzofitimod in Pulmonary Sarcoidosis

Sep 24, 2026, 6:26 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory alignment for a Phase 3 program is a meaningful progression milestone that can reprice risk-adjusted expectations; potential upside depends on capital strategy and eventual trial results, but the milestone itself is positive.

AI summary

What happened, with direct paths to the underlying reporting

ATYR announced FDA alignment on a Phase 3 protocol for efzofitimod in pulmonary sarcoidosis with restrictive lung disease, centering on FVC change at week 48. The 54-week global trial plans two cohorts (up to 372 patients) with IV dosing every 3 weeks and US/Europe regulatory submissions planned for late 2026. Ongoing financing needs and execution risk will influence timing and potential upside.

FDA aligned on Phase 3 efzofitimod protocol for pulmonary sarcoidosis; study activities to start Q4 2026.
Global 54-week Phase 3: two cohorts, 5.0 mg/kg, up to 372 patients, IV every 3 weeks.
Primary endpoint: FVC change at week 48; KSQ-Lung score as key secondary.
Funding will require additional capital via equity, debt, grants, or partnerships.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

aTyr Aligns Phase 3 Protocol for Efzofitimod in Pulmonary Sarcoidosis

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

aTyr Pharma's lung disease drug misses main goal in late-stage trial